Anhisan

Nicardipine HCl.

Each mL contains: Nicardipine Hydrochloride 1 mg.

Pharmacology: Drug Mechanism: Nicardipine Hydrochloride shows vasodilatory effects by inhibiting the entry of Ca⁺⁺ into vascular smooth muscle cells. Nicardipine Hydrochloride shows the action of Ca⁺⁺ antagonists in vascular smooth muscle 30,000 times more than the heart muscle, and higher vascular selectivity than other Ca⁺⁺ antagonists.

Emergency treatment of acute hypertensive crises during surgery.
Hypertensive emergencies.

Emergency treatment of acute hypertensive crisis during surgery: ANHISAN Injection is diluted with physiological salt or 5% glucose so that it becomes a solution of 0.01-0.02% Nicardipine Hydrochloride (0.1-0.2 mg/mL). The solution is given by intravenous drip infusion with a speed ranging from 2 to 10 μg/kg/minute until the desired blood pressure value is reached and adjusted for monitoring to maintain blood pressure. For rapid blood pressure reduction, ANHISAN Injection is given intact at a dose of 10 to 30 μg/kg by intravenous injection.
Emergency hypertension: ANHISAN Injection is diluted with isotonic sodium chloride solution or 5% glucose injection to make a solution of 0.01-0.02% Nicardipine Hydrochloride (0.1-0.2 mg/mL). The solution is given by intravenous drip infusion at a rate of 0.5-6 μg/kg/minute until the desired blood pressure is reached and adjusted for monitoring to maintain blood pressure.

ANHISAN Injection is contraindicated in the following patients: Patients recovering with incomplete hemostasis after intracranial bleeding (Bleeding can be stimulated).
Patients with increased pressure in acute stroke in the brain, (intracranial pressure may be higher).
Patients with medical hypersensitivity news on this product.

In patients with emergency hypertension, if necessary to control blood pressure after getting the desired blood pressure and if oral administration allows replacement with oral medication should be done.
In patients with hypertensive emergencies, it is reported that blood pressure may increase again on cessation of Nicardipine. Therefore, the dose of Nicardipine must be reduced gradually and blood pressure carefully controlled after the product is stopped. Furthermore, after being replaced with oral medication, patients must be warned of increased blood pressure.
Giving with caution: Careful administration: (Nicardipine injection must be given carefully to the following patients).
Patients with kidney or liver dysfunction. (This product is metabolized in the liver. In general, acute hypotension in patients with severe renal dysfunction can cause renal hypofunction).
Patients with aortic stenosis, (this symptom can be bad).
Important prevention: Because the effect of this product may be different for each patient, this product must be given carefully under close monitoring of blood pressure and heart rate.
If hypotension is clearly caused by an overdose by this product, administration must be stopped. If rapid recovery from blood pressure is needed, vasopressors (norepinephrine) should be given.
If there is pain or redness appear at the injection site after long-term use of this product, the injection site must be changed.
Other Precautions: In patients in the postoperative monitoring period after open heart surgery, it is known that some patients can experience circulatory failure and show symptoms of heart failure. The efficacy of this product for these patients is unknown because there are only a few cases.
Use in Pregnancy and Lactation: This product should only be used on pregnant women and women suspected of being pregnant provided the expected therapeutic benefits exceed the risk of treatment.
Use of this drug is not recommended during breastfeeding. If use during breastfeeding is needed, the patient must stop breastfeeding.
Use in Children: Product safety in premature infants, newborns, infants who breastfeed, infants and children is unknown.
Use in Elderly: Because parents have physiological hypofunction (liver, ginal, etc.), it is recommended to start low-dose treatment (eg intravenous drip drops at 0.5 μg/kg/minute) which continues with careful monitoring.

This product should only be used on pregnant women and women suspected of being pregnant provided the expected therapeutic benefits exceed the risk of treatment.
Use of this drug is not recommended during breastfeeding. If use during breastfeeding is needed, the patient must stop breastfeeding.

Emergency treatment of acute hypertensive crisis during surgery: The main side effect is tachycardia.
Emergency hypertension: The main side effect is facial redness.
Significant side effects: Paralytic ileus: Paralytic ileus can occur. If abnormal signs arise, they must be taken and the right steps must be taken.
Hypoxemia: Hypoxemia may occur rarely. If abnormal signs arise, they must be taken and the right steps must be taken.
Angina pain: (Case abroad) It takes less than 1% of patients approved by this injection of angina or increased exacerbation. If signs occur, the administration must be stopped and appropriate steps should be taken.
Thrombocytopenia: Thrombocytopenia can occur. The patient must be observed carefully, and if abnormal signs arise, administration must be stopped and appropriate steps must be taken.
Impaired liver function and jaundice: Impaired liver function associated with increased AST (GOT), ALT (GPT) or γ-GPT and jaundice can occur. The patient must be observed carefully, and if abnormal signs arise, administration must be stopped and appropriate steps must be taken.
Other adverse reactions: see Table 1.


Click on icon to see table/diagram/image

Nicardipine injection must be given with caution if it is accompanied by the following medication: see Table 2.


Click on icon to see table/diagram/image

Preparation of drip injection solutions: For intravenous drip infusion, 0.01%-0.02% of the Nicardipine Hydrochloride solution is made by adding the required volume of Nicardipine injection to the infusion fluid suitable for use together with Nicardipine injection.
Refer to table as follows: see Table 3.


Click on icon to see table/diagram/image


Precautions about use: During preparation: In drip i.v this product, Nicardipine Hydrochloride can crystallize because of the high pH of the infusion fluid or for other reasons, therefore, attention must be paid to the possibility of crystallization.
Because until now, the injection solutions mentioned as follows were found to be incompatible with this product, this solution cannot be combined with this product.
Furosemide, Potassium canrenoate, Aminophylline, Sodium bucladesine, Amrinone, Lidocaine, Iohexol, Iopamidol, Tranexamic Acid, Sodium sulfonate Carbazochrome, Sodium heparin, Urokinase, Tisokinase, Alteplase, Phosphomycin, Cefotiam dihydrochloride, Cefuzonam sodium, Imipenem, Flomoxef sodium, Sodium bicarbonate.
This product is available as an ampoule.
The cutting point of the ampoule must be cleaned with alcohol cotton before opening.

Store below 30°C, away from light.

Calcium Antagonists

C08CA04 - nicardipine ; Belongs to the class of dihydropyridine derivative selective calcium-channel blockers with mainly vascular effects. Used in the treatment of cardiovascular diseases.

K